Rita Axelrod
Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (16)
Figure s4. Gene set enrichment analysis (GSEA) across baseline responder vs. nonresponder comparisons and baseline vs. post-treatment analyses in the durvalumab-metformin clinical trial and other clinical trial cohorts. GSEA was performed to assess differences between baseline responders and nonresponders, as well as baseline vs. post-treatment samples
Year:
2025
Purpose: Immune checkpoint inhibitors (ICI) have demonstrated clinical benefit in head and neck squamous cell carcinoma (HNSCC); however, single-agent efficacy is limited, leaving significant unmet needs. Metformin may synergize with ICIs, offering promise to improve response rates. We leveraged multiomic data from a randomized, presurgical neoadjuvant trial (NCT03618654) evaluating a single infusion of the anti–PD-L1 ICI durvalumab with or without daily, standard dose metformin in previously untreated, nondiabetic patients with HNSCC to understand predictors of response and the effect of combination therapy. Patients and Methods: Clinical, pathologic, and correlative data were analyzed to investigate response and resistance mechanisms. We present an in-depth multiomic analysis of primary tumor specimens to study treatment response/resistance in human papillomavirus–positive HNSCC. Results: Baseline samples revealed that myofibroblastic cancer-associated fibroblast and extracellular matrix signatures were enriched in durvalumab plus metformin nonresponders, which were localized to the leading tumor edge on spatial transcriptomics. In contrast, baseline responder samples were enriched for the Langerhans-like dendritic cell (DC) state and IFN signatures. Treatment increased intratumoral CD8 + T-cell and IFN signatures and peripheral blood CCL2 levels. Responders demonstrated macrophage and DC enrichment and antigen processing and presentation upregulation. Enrichment of cell cycle–related gene sets, specifically the MYC targets V1 hallmark gene set, correlated with nonresponse. Conclusions: Early response and resistance dynamics for durvalumab plus metformin in human papillomavirus–positive HNSCC reveal baseline extracellular matrix–myofibroblastic cancer-associated fibroblast as predictive of nonresponse. In contrast, responders were distinguished by baseline enrichment in the Langerhans-like DC state and posttreatment antigen-presenting gene sets.
Year:
2025
Figure s5. Baseline immune cell composition in responders and nonresponders across bulk, tumor, and stromal compartments & Immune cell deconvolution analysis in bulk tumor samples of responders and nonresponders before and after durvalumab-metformin treatment.
Year:
2025
Figure s11. Carcinoma ecotype differences at baseline and after treatment in HPV+ HNSCC responders and non-responders. This figure illustrates differences in carcinoma ecotype composition before and after treatment in HPV+ HNSCC patients
Year:
2025
Supplement Figure 3: Signature-based Biomarkers. A: Signature-Based biomarkers for HPV negative patients. B: Signature-based biomarkers for HPV positive patients. ‘Primary Path Response’ refers to analysis based on the pTR at the primary site alone. ‘Overall path response’ refers to analysis based on primary + lymph node response.
Year:
2025
Supplement Figure 1: Waterfall Plots. A: Degree of pathologic treatment response (pTR) at the lymph nodes. B: Degree of pathologic response at the primary site, stratifed by treatment arm. C: Degree of RECIST response of primary tumor site (yellow) and lymph nodes (purple), stratifed by treatment arm.
Year:
2025
Supplement Table 4A-4B: The following is a comprehensive list of the top 20 functional enrichments in the B cell (A) and CAF2 (B) gene sets utilizing STRING database to analyze protein-protein interaction pairs among the leading edge.
Year:
2025
Supplement Table 2A-2E: GSEA quantitative data for the B cell gene sets and CAF2 gene set for Post- vs Pre-treatments Responders vs Non responders. The following is a comprehensive list of supervised B-cell (A-C) and CAF (D-E) enrichment scores, normal enrichment scores, p-values, and q-values for the included gene sets.
Year:
2025
Supplementary Figure 2: Effect of IDO inhibitor BMS986205 on response rate and the tryptophan kynurenine pathway. A and B: IDO1 gene expression levels and tryptophan kynurenine pathway activity score, respectively, compared between baseline samples of responders (R) and non-responders (NR) on nivolumab + BMS986205 and nivolumab-only therapies. C: Tryptophan kynurenine pathway activity score compared between baseline and post-treatment samples of R and NR on nivolumab + BMS986205 and nivolumab-only therapies. - ns, *p
Year:
2025
Purpose: Neoadjuvant chemotherapy for structure preservation (SP) in nasal and paranasal sinus squamous cell carcinoma (NPNSCC) has been described in single-institution studies but not in randomized studies. EA3163 was a randomized study investigating whether cytoreductive neoadjuvant chemotherapy would improve SP or overall survival (OS). Patients and Methods: Patients with T3/T4a and select T4b NPNSCC requiring orbital or base of skull (BOS) resection were randomized to surgery (arm A) versus surgery preceded by docetaxel/cisplatin for three cycles (arm B). The degree of anticipated SP (orbit and BOS) was required preoperatively and after chemotherapy. SP was noted at surgery. Co-primary objectives were the SP rate (orbit/BOS) and OS. Eighty-two patients needed to be accrued for 81% power with a 0.1 one-sided alpha using Fisher’s exact test for SP rate and 83% with a 0.1 one-sided alpha using the log-rank test for OS. Results: Among 23 evaluable patients, the overall SP rate was 30%: 15% in arm A ( N = 2/13; 95% confidence interval (CI), 1.9%–45.4%) and 50% in arm B ( N = 5/10; 95% CI, 18.7%–81.3%; P = 0.17). Among 18 patients with pathologic T3/T4a disease, the overall SP rate was 39%: 18% in arm A ( N = 2/11; 95% CI, 2.3%–51.8%) and 71% in arm B ( N = 5/7; 95% CI, 29.0%–96.3%; P = 0.049). Orbit and BOS-specific preservation rates were 38% (95% CI, 8.5%–75.5%) versus 83% (95% CI, 35.9%–99.6%) and 33% (95% CI, 9.9%–65.1%) versus 67% (95% CI, 29.9%–92.5%) in arm A versus B, respectively. The most common grade ≥3 toxicities included mucositis, anemia, nausea and lymphopenia (all >10%). No grade 5 events were reported. Conclusions: These results support neoadjuvant chemotherapy as an effective intervention for SP in T3/T4a NPNSCC and deserve further evaluation.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Collaborators (30)
Andrew South
Oros Family Professor in Rare Skin Diseases
University of Wisconsin-Madison
Fenghai Duan
Professor
Brown University
Christopher Le
Professor
University of Arizona College of Medicine
Megan Roche
Thomas Jefferson University
Ramkrishna Mitra
Assistant Professor
Thomas Jefferson University
Nabil F. Saba
-
Nolan B. Seim
Assistant Professor
Ohio State University
David Cognetti
department of surgery thomas jefferson university hospital sidney kimmel medical college philadelphia university and tho
Peter H. Hwang
-
Joseph Curry
Associate Professor
Thomas Jefferson University Hospital
Tingting Zhan
Associate Professor
Thomas Jefferson University
Rathan M. Subramaniam
Duke University
George Prendergast
Professor, President & CEO
Lankenau Institute for Medical Research
Ehab Y. Hanna
-
Barbara Burtness
Professor
Yale University School of Medicine
Hushan Yang
Professor
Thomas Jefferson University
Benjamin Leiby
Professor
Thomas Jefferson University
Charalambos Solomides
Professor
Thomas Jefferson University
Rajanikanth Vadigepalli
Thomas Jefferson University
Paul Swiecicki
University of Michigan
Scott W. Keith
Thomas Jefferson University
Larry Harshyne
Associate Professor
Thomas Jefferson University
Carl Snyderman
Professor
University of Pittsburgh
Jennifer M. Johnson
Thomas Jefferson University
Dong M. Shin
Professor
Emory University
Chukwuemeka Ikpeazu
Associate Professor
University of Miami Miller School of Medicine
John R. Eisenbrey
Thomas Jefferson University
Ubaldo Martinez-Outschoorn
Associate Professor
Thomas Jefferson University
Stacey Gargano
Thomas Jefferson University Hospital
Adam J. Luginbuhl
-
Make your next move.
Prepare your application
Review drafts before you send them.